This is a long-term rollover follow-up study for Phase I/II study (Protocol EXG-US-01).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of participants with adverse events -Safety by Incidence of Treatment-Emergent
Timeframe: Change from Baseline Systolic Blood Pressure at Month 18, 24,30,36,42,48,60 and 72
umber of participants with a change in in physical examination
Timeframe: Change from Baseline Systolic Blood Pressure at Month 18, 24,30,36,42,48,60 and 72
Number of participants with a change in Electrocardiography (ECG)
Timeframe: Change from Baseline Systolic Blood Pressure at Month 18, 24,30,36,42,48,60 and 72
Number of participants with a change in clinical laboratory evaluations
Timeframe: Change from Baseline Systolic Blood Pressure at Month 18, 24,30,36,42,48,60 and 72
Number of participants with a change of Immunogenicity
Timeframe: Change from Baseline Systolic Blood Pressure at Month 18, 24,30,36,42,48,60 and 72